APA (7th ed.) Citation

H, L., H, C., T, L., X, C., H, Y., J, S., & Y, Y. Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study. Dove Medical Press.

Chicago Style (17th ed.) Citation

H, Liu, Cao H, Li T, Chen X, Yu H, Sun J, and Yu Y. Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study. Dove Medical Press.

MLA (9th ed.) Citation

H, Liu, et al. Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I Study. Dove Medical Press.